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Abstract
Background: Falls may lead to hip fractures, which have a detrimental effect on the prognosis of patients as well
as a considerable impact on healthcare expenditures. Since a secondary hip fracture (SHF) may lead to even higher
costs than primary fractures, the development of innovative services is crucial to limit falls and curb costs in high-
risk patients. An early economic evaluation assessed which patients with a second hip fracture could benefit most
from an exoskeleton preventing falls and whether its development is feasible.
Methods: The life-course of hip fractured patients presenting with dementia or cardiovascular diseases was
simulated using a Markov model relying on the United Kingdom administrative data and complemented by
published literature. A group of experts provided the exoskeleton parameters. Secondary analyses included a
threshold analysis to identify the exoskeleton requirements (e.g. minimum impact of the exoskeleton on patients’
quality of life) leading to a reimbursable incremental cost-effectiveness ratio. Similarly, the uncertainty around these
requirements was modelled by varying their standard errors and represented alongside population Expected Value
of Perfect Information (EVPI).
Results: Our base-case found the exoskeleton cost-effective when providing a statistically significant reduction in
SHF risk. The secondary analyses identified 286 cost-effective combinations of the exoskeleton requirements. The
uncertainty around these requirements was explored producing further 22,880 scenarios, which showed that this
significant reduction in SHF risk was not necessary to support the exoskeleton adoption in clinical practice.
Conversely, a significant improvement in women quality of life was crucial to obtain an acceptable population EVPI
regardless of the cost of the exoskeleton.
Conclusions: Our study identified the exoskeleton requisites to be cost-effective and the value of future research.
Decision-makers could use our analyses to assess not only whether the exoskeleton could be cost-effective but also
how much further research and development of the exoskeleton is worth to be pursued.
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Background
Falls have a detrimental impact on mortality, morbidity
and Health-Related Quality of Life (HRQOL) since they
may lead to traumatic events, such as hip fractures [1–3].
In the United Kingdom (UK), the latest estimates of the
health and social costs of hip fractures range from £2 to £3
billion. These costs are expected to increase further by
2025 mainly because of osteoporosis-related fractures
[2, 4–6]. Secondary hip fracture (SHF) may lead to even
larger costs than primary fractures, mainly due to the
likely increase in duration of hospitalisation [2, 7].
Some comorbidities, such as dementia and cardiovascu-
lar disease (CVD), are known to impair the gait and as
such are important risk factors for SHFs [8]. Therefore,
there is an increasing interest in the identification of
cost-effective interventions to prevent falls, boosting
research and development of innovative technologies in
this area [9–12].
A recent study suggested that robotic exoskeletons
could avoid falls, but more evidence would be needed to
decide whether it would be a cost-effective intervention
to prevent SHFs [13]. Given the limited evidence on the
exoskeleton effectiveness, traditional Health Technology
Assessment (HTA) methods would not be sufficient to
assess the device cost-effectiveness. Nevertheless, an
economic evaluation could be performed by using early
HTA approach. Early HTA is defined as the collection
of methods used to inform decision makers, and manu-
facturers, on the possible value of a technology in devel-
opment and includes methods to manage and quantify
uncertainty [14]. An intrinsic characteristic of the evalu-
ation of technologies at their early stage is the dearth of
reliable parameters, which can often only be obtained by
use of elicitation methods. Decision models employing
these methods will provide valid estimates insofar the
elicited values are confirmed by future studies. Even if
elicited values are confirmed by future evidence, they do
not necessarily represent the minimum requirements to
ensure the cost-effectiveness of a technology. For
example, elicited values do not provide information on
what is the minimum average health effect, and the rela-
tive uncertainty, necessary to justify the cost of an inter-
vention. A sequence of threshold analyses could identify
these requirements as well as express their uncertainty
in terms Value of Information (VOI). VOI is used in de-
cision analysis to represent simultaneously the probabil-
ity that a decision will be wrong and its consequences in
the same terms of value as the decision being made [15].
Then, VOI could be interpreted as the upper limit to
fund additional research to resolve all uncertainty in
current available evidence. Therefore, providing an esti-
mate of the minimum cost-effectiveness requirements
expressed in terms of VOI could inform not only the
manufacturer but also decision-makers on whether these
requirements are achievable and, more importantly,
worthy of pursuance [16].
In this respect, the substantial costs to fund new re-
search may raise important questions for the technology
and its potential users. For example, (i) which subpopu-
lation of patients may benefit most from the use of the
new technology, (ii) what are, on average, the minimum
requirements for the technology to be cost-effective, (iii)
what is the maximum uncertainty around these require-
ments to justify future research, and (iv) are the values
identified in (ii) and (iii) achievable? An early economic
evaluation of an exoskeleton able to prevent falls is used
as case study to illustrate this process. The current
case study uses a sequence of threshold analyses to
answer questions (i) to (iii). In doing so, this analysis will
support the decision on whether the further research and
development of the exoskeleton is worthwhile (i.e. ques-
tion iv).
Methods
We performed an early cost-effectiveness analysis of a
robotic exoskeleton, by simulating its use both in a care-
home and in patients’ home settings, in addition to UK
standard post-hip fracture care [13, 17].
Our analyses are based on a previously published Markov
model developed in Excel (Microsoft, Redmond, WA)
[7, 17]. The model described the natural history of
patients with hip fractures and, by doing so, estimated
the life-expectancy trajectories, allowing us to calculate
the lifetime costs and Quality Adjusted Life Years (QALYs)
of the simulated patients. These estimates were conditional
on health states reflecting the natural history of hip frac-
ture: history of primary hip fracture, second hip fracture
and major non-hip fractures (e.g. wrist, spine, humerus)
necessitating hospitalisation. These states were imple-
mented both in a care-home and own home settings. Death
was modelled as 30-day mortality after a fracture or within
a year. Once patients were moved to a care-home, they
were not modelled to return to their own home. The cycle
length used was one year, applying a half-cycle correction.
A 3.5% annual discount rate was applied to costs (2012/
2013 UK sterling) and to QALYs [17]. The model sche-
matic is depicted in the Additional file 1: Appendix 1.
Target population
The population simulated in our model reflects the
characteristics of the UK population who had experi-
enced a hip fracture observed between 2003 and 2013.
Our analyses focused on high-risk subpopulations and
included patients with dementia and patients with CVD
(i.e. stroke, myocardial infarction) [7, 8]. The subgroups
explored in our analyses were sex and age specific risks
at 65, 75 and 85 years old.
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Model parameters
The model was parameterised using an extract of the
Hospital Episode Statistics (HES) dataset and supple-
mented by published literature [7, 17]. This extract
included 33,152 individuals older than 60 years who had
an emergency admission for a hip fracture coded with
an ICD-10 diagnosis code S72.0- S72.2 or S72.9. These
data informed the model on the probabilities of having a
fracture, being discharged to a care-home and dying.
Similarly, HES data were used to calculate the cost of
hospitalisations relative to the model health states. Infor-
mation on primary care visits, drug consumption and
laboratory tests were obtained from an extract of the
Clinical Practice Research Datalink (CPRD) dataset. This
extract included 4063 patients who had a link to hospital
admission due to a hip fracture and was used to estimate
the primary care costs for each health state in the model.
Additional file 1: Appendices 2 and 3 show the risk
equations and events probabilities that informed the
model. More detail of our methodology has been previ-
ously reported [7, 17].
Subpopulations were modelled by adjusting the stand-
ard population mortality and the probability of having a
SHF. The equations estimating mortality at 30 days after
an SHF surgery used as a covariate the Charlson Comor-
bidity Index (CCI). The 30-day mortality was calculated
assuming a score of 2.2 for both the CVD and dementia
subpopulations. The probability of having a second hip
fracture in dementia and CVD subpopulation was updated
using odds ratios from a previously published meta-analysis,
respectively 1.89 (95% confidence interval [95% CI]:
1.47 to 2.43) and 1.32 (95% CI: 1.02 to 1.70) [8]. Additional
file 1: Appendix 4 shows the parameters used to model the
subpopulations.
Quality of life
A meta-regression, employing a mixed-effect model, es-
timated the utilities obtained from 21,085 patients from
32 studies assessing preference-based quality of life for
individuals with hip fracture. This model was used to
predict the utility values of non-comorbid population
patients and was assumed to remain constant after the
first year following a hip fracture (0.66). The impact of a
second hip fracture and a major non-hip fracture on
the HRQOL were assumed to be comparable and,
therefore, were represented by the same utility (0.44)
[17]. Additional file 1: Appendix 5 shows the coeffi-
cient of the model used to calculate the utility scores.
The disutilities of the CVD (ICD-9 codes 412 and 433)
and dementia (ICD-9 code 331) subpopulations were
obtained from Sullivan et al. [18]. These disutilities were
modelled as a decrement relative to the general popula-
tion and, therefore, the utilities were reduced by 4% for
CVD patients and 26% for dementia patients.
Costs
The perspective of the National Health Service (NHS) in
England and personal social services (PSS) was adopted,
including primary and secondary healthcare and care-
home costs. Costs considered are those both related and
unrelated to hip fractures. Primary care expenditures
were comprised of practice nurse and GP contacts, as
well as visits to other healthcare personnel, such as
health visitors or physiotherapists, drugs and laboratory
tests. Secondary healthcare costs included accident and
emergency contacts, outpatient visits, inpatient admissions
and day cases. The cost of walking aids, home adaptations
or home care were not included since these are funded by
councils or local organisations. Comorbidities were found
to be an important predictor for the cost of primary hip
fracture, but not for secondary (or later) fractures [7].
Therefore, we assumed the costs due to SHFs in dementia
and CVD subpopulations were comparable to the popula-
tion without comorbidities. Additional file 1: Appendices
6–8 show the equations used to calculate the costs that
informed the decision model.
Exoskeleton parameters
The parameters used in the base-case, and their respect-
ive uncertainty, were obtained through semi-structured
interviews of experts. The group of experts composed of
the developers of the exoskeleton and a senior orthopae-
dics consultant of a hospital (i.e. ASL Nord-Ovest) in
Tuscany (Italy). The engineers expected their exoskel-
eton to decrease the number of falls leading to SHFs by
25%. This reduction was modelled as a hazard ratio
(HR), and the standard error was assumed to be 40% of
this estimate on the logarithmic scale. The senior con-
sultant found this HR plausible and believed this would
increase the patients’ HRQOL by 70%. The additional
uncertainty around the HRQOL due to the device was
incorporated in the model inflating the utility estimates
of the subpopulations by 40%. The base-case assumed that
the exoskeleton was provided to the NHS at an annual
cost of £6000, including servicing costs. Additional file 1:
Appendix 4 shows the exoskeleton parameters.
Analysis
A probabilistic sensitivity analysis was performed to esti-
mate the uncertainty around the costs and QALYs in
each group. The convergence of the model was tested by
considering an increasing number of simulations until a
stable estimate of costs and QALYs was obtained. In
doing so, it was determined that the model converged
using 1000 simulations. Based on these simulations, we
calculated the between groups differences in costs and
QALYs. The uncertainty around these mean differences
was reported using a non-parametric 95% CI. The differ-
ence in costs was combined with the difference in QALYs
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to calculate the Incremental Cost-Effectiveness Ratio
(ICER) of the exoskeleton. To assess the value for money
of the exoskeleton, ICERs were compared to a cost-
effectiveness threshold of £20,000 per QALY [19]. Assum-
ing that this estimate represents the actual monetary value
of a QALY allowed us to calculate the expected value of
perfect information (EVPI) for the UK population. To
calculate the population EVPI, the cumulative number of
hip fractured patients, with either CVD or dementia, in
the next 10 years was multiplied by the EVPI [7, 20]. Our
base-case results are presented by sex, comorbidity and
age bands, namely: 65, 75, and 85 years of age. Secondary
analyses were performed in two steps, namely threshold
and uncertainty analyses.
Threshold analysis
The threshold analysis aimed at answering questions (i)
and (ii) outlined in the background. To identify which
patients may benefit most from the use of the exoskeleton
(i.e. question (i)), the average minimum requirements for
the technology to be cost-effective (i.e. question (ii)) were
identified for each subgroup.
The threshold analysis assumed that there was no
uncertainty around the parameters of the exoskeleton.
In this respect, the value of the HR of falling of patients
wearing the exoskeleton and their HRQOL utility-ratio
were kept constant (i.e. deterministic) over the 1000
simulation of each scenario. The scenarios included in
the threshold analysis were obtained by combining arbi-
trary values of HR of falling wearing the exoskeleton to
values of the HRQOL of the patients using the device.
The HR of falling ranged from 0.5 to 1.125, and the
intermediate scenarios were based on intervals of 0.125.
Similarly, the HRQOL of the patients wearing the device
was adjusted by utility-ratios ranging arbitrarily from
0.90 to 1.70, using intervals of 0.05. Figure 1 (panel a)
depicts these scenarios.
For example, scenario 1a assumed that the HR of fall-
ing with the exoskeleton is 0.5 and the utility-ratio is
equal to 0.90. Based on these values, a thousand simula-
tions were obtained and stored for scenario 1a. Then, it
was assumed that the HR of falling was still equal to 0.5
and the utility-ratio was increased from 0.90 to 0.95 to
obtain scenario 2a. Based on this new set of values, 1000
runs were simulated and recorded for scenario 2a. These
steps are repeated until the largest utility-ratio consid-
ered in our analysis was combined with the HR of falling
equal to 0.5 (i.e. scenario 17a). This process was per-
formed for the other scenarios of the HR of falling,
namely assuming that the HR of falling is equal to 0.625,
0.75, 0.875, 1, or 1.125.
This iterative approach was performed for all the con-
sidered age bands (i.e. 65, 75 and 85 years), sex, comor-
bidities (i.e. CVD, dementia), risk-sharing agreement (i.e.
leasing or purchase) and the respective cost of the device
(leasing cost: £3000, £4000, £5000 and £6000; purchase
Fig. 1 Schematic of the secondary analyses: (a) Threshold analysis, (b) Uncertainty analysis
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cost: £12,500, £15,000, £17,500 and £20,000). The
‘purchase’ scenarios assumed that costs were irreversible,
the exoskeleton lifespan was 5-years and the annual
maintenance costed £2500 per year [21]. As a result of
this process, 9792 scenarios were obtained and 1000
simulations were stored for each scenario. All the 1000
simulations were used to calculate an ICER per scenario.
The scenarios providing an ICER below £20,000 per
QALY, which are shaded in green and yellow in Fig. 1
(panel a), were retained and further analysed. Based on
the considered discrete values of the HR of falling, the
scenarios presenting the lowest utility-ratio but still lead-
ing to an ICER below £20,000 per QALY (i.e. yellow
shaded scenarios in Fig. 1; panel a) represent the exoskel-
eton requirements to be cost-effective. These requirements
were employed in the uncertainty analysis.
Uncertainty analysis
The exoskeleton requirements obtained in the threshold
analysis were used to inform the uncertainty analysis,
which aimed at answering question (iii) reported in the
background. The uncertainty around these requirements
was modelled in 80 further scenarios, which were
obtained by combining arbitrary values of the standard
errors of the exoskeleton requirements. The standard
error applied to the exoskeleton HR of falling ranged
from 1.05 to 1.40, employing intervals of 0.05. The
standard error of the HRQOL utility-ratio was increased
from 0.25 to 2.5 by intervals of 0.25. The uncertainty of
the exoskeleton HR and utility-ratio were modelled with
a log-normal distribution. All possible combinations of
the standard errors outlined above were combined and
presented in in Fig. 1 (panel b). The overall model uncer-
tainty of each scenario was then quantified by calculating
the population EVPI.
For example, assuming that the threshold analysis de-
termined that the exoskeleton is cost-effective if the
average HR of falling is equal to 0.5 and the average
utility-ratio if equal to 1.35 (i.e. scenario 10a of Fig. 1;
panel a), the standard errors around these values were
varied in 80 scenarios. In this sense, the standard error
of the HR of falling is initially set equal to 1.05 and the
standard error of the utility-ratio is set to 0.25 (i.e. sce-
nario 1b of Fig. 1; panel b). Based on these values of the
parameters and their uncertainty (i.e. standard error),
1000 simulations were obtained and stored. Then,
assuming the standard error at the HR of falling is still
equal to 1.05, the standard error of the utility-ratio was
increased from 0.25 to 0.5 (i.e. scenario 2b of Fig. 1;
panel b) and 1000 runs were again obtained and re-
corded. These steps are repeated until the largest stand-
ard error considered for the utility-ratio (i.e. scenario
10b of Fig. 1; panel b) was combined with the standard
error of the HR of falling equal to 1.05. The process for
the considered threshold value (i.e. average HR of falling
equal to 0.5 and utility-ratio equal to 1.35) ended when
the steps outlined above were performed for all the
scenarios of the standard errors of HR of falling, namely
assuming that the standard error is equal to 1.1, 1.15,
1.2, 1.25, 1.3, 1.35 or 1.4.
This iterative approach was performed for each
scenario identified in the threshold analysis – which are
shaded in yellow in Fig. 1 (panel a). The stored results
were used to obtain non-parametric 95% CI of the HR
of falling and HRQOL utility-ratio of each scenario, and
to calculate the respective population EVPI. These results
were analysed using quantile regressions to describe the
95% confidence intervals of the threshold values as a func-
tion of the population EVPI. Additional file 1: Appendices 9
and 10 show the coefficients of these quantile regressions.
Results
Base-case
The Markov model simulated cohorts of 1000 patients
to reflect the characteristics of dementia and CVD pa-
tients accessing a hospital because of a hip fracture in
the UK. Table 1 shows our base-case results by sex and
age bands. Our model showed that the exoskeleton
could lead to a substantial increment of QALYs regard-
less of patients’ age and comorbidities. For patients with
CVD, the exoskeleton is estimated to be cost-effective
only in CVD patients younger than 75 years (ICER
(female): £18,753; ICER (male): £19,598). For dementia
patients, the exoskeleton is similarly cost-effective in
preventing SHF only in individuals not older than 75
years. The ICER for dementia patients ranged from £18,
083 (65-year-old female) to £19,900 (75-year-old male).
The 95% CIs of the HR and HRQOL utility-ratio
ranged from 0.60 to 0.94 and from 1.46 to 1.93, respect-
ively. As a result of these uncertainties, the population
EVPI of cost-effective scenarios for female patients
ranged from £12,058,172 (CVD - 65 years old) to £29,
986,626 (dementia - 75 years old), whilst the population
EVPI for 65-year-old women with dementia was £20,
332,551. The smaller proportion of male patients experi-
encing a hip fracture, approximately 25% of the HES
extract, [7, 17] was reflected by the population EVPI,
which ranged from £5,275,225 (CVD - 65 years old) to
£9,920,712 (dementia - 75 years old). The population
EVPI for male patients aged 65 with dementia was £5,
460,316.
Threshold analysis
Figure 2 depicts the probability of cost-effectiveness of
each examined scenario on a chromatic scale ranging
from red (i.e. not cost-effective) to green (cost-effective).
Panels A and B report the cost-effectiveness results for
the “leasing” scenarios, whilst panels C and D depict the
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Table 1 Base-case: Lifetime costs and QALYs of cardiovascular disease and dementia hip fractured populations by sex and age
Exoskeleton Usual care Difference (95% Confidence Interval)
Costs QALYs Costs QALYs Cost QALYs ICER
Cardiovascular disease
Female
65 years old £104,735 7.26 £59,588 4.85 £45,147(£41,350 to £49,207) 2.41(1.91 to 2.97) £18,753
75 years old £80,067 4.40 £52,210 3.01 £27,857(£26,332 to £29,680) 1.39(1.13 to 1.63) £20,041
85 years old £60,162 2.44 £43,972 1.74 £16,190(£15,530 to £16,894) 0.7(0.59 to 0.8) £23,169
Male
65 years old £84,062 5.28 £50,867 3.59 £33,195(£30,346 to £35,895) 1.69(1.32 to 2.09) £19,598
75 years old £61,070 2.97 £41,674 2.09 £19,396(£18,188 to £20,534) 0.88(0.69 to 1.04) £22,122
85 years old £44,656 1.53 £33,817 1.15 £10,839(£10,332 to £11,355) 0.38(0.32 to 0.44) £28,467
Dementia
Female
65 years old £105,299 6.14 £60,854 3.68 £44,445(£40,793 to £48,371) 2.46(1.66 to 3.2) £18,083
75 years old £80,461 3.74 £53,076 2.29 £27,385(£25,869 to £29,187) 1.44(1.04 to 1.81) £18,971
85 years old £60,384 2.10 £44,478 1.34 £15,906(£15,256 to £16,602) 0.75(0.58 to 0.93) £21,091
Male
65 years old £84,393 4.51 £51,668 2.74 £32,725(£29,951 to £35,362) 1.77(1.25 to 2.31) £18,476
75 years old £61,303 2.57 £42,208 1.61 £19,094(£17,918 to £20,195) 0.96(0.72 to 1.19) £19,900
85 years old £44,801 1.36 £34,134 0.90 £10,667(£10,162 to £11,169) 0.46(0.36 to 0.56) £23,341
Fig. 2 Threshold analysis: Cost-effectiveness heat map of cardiovascular and dementia hip fractured populations by sex and age. Legend: Green
(cost-effectiveness probability = 1); red (cost-effectiveness probability = 0)
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“purchase” scenarios, for CVD and dementia cohorts.
The vertical axis of each figure in the panels reports the
exoskeleton HR, the HRQOL utility-ratio is represented
on the horizontal end.
Leasing
The importance of HRQOL across the leasing scenarios is
more prominent than fall prevention (Fig. 2; panels a and b).
The exoskeleton was not cost-effective unless it
provided a gain in patients’ HRQOL by 25% paired to a
HR of falling of 0.625. However, the reduction in the
number of second hip fractures was not a limiting factor
for cost-effectiveness, especially in less expensive scenar-
ios. The largest HR of falling that still ensured the
device’s cost-effectiveness was 1.125, however, this
scenario needs to be paired with a larger increment in
HRQOL, namely 30%. Conversely, the prevention of hip
fractures had a relevant impact in scenarios simulating
more expensive leasing fees (e.g. £6000 annual leasing).
These fees could be justified only if the exoskeleton was
not inferior to usual care, and would provide on average
a larger improvement in patients’ HRQOL.
The proportion of cost-effective scenarios did not ma-
terially differ between disease groups, regardless of sex.
Purchase
Compared to the leasing scenarios, purchasing the device
(Fig. 2; panels c and d) was less likely to be a cost-effective
alternative. In this respect, the HRQOL influences the
results of the purchase scenarios to a smaller extent than
it did for the leasing scenarios.
Overall, to represent good value for money, the device
should provide at least an increment of patients’ HRQOL
by 48% alongside an HR of falling of 50% SHF. Similarly
to the leasing scenarios, the HR of falling does not influ-
ence predominantly the cost-effectiveness of the device
(i.e. the threshold value is 1.25), but the increment in
HRQOL will need to be substantially large, namely 57.5%.
Selling the device is more likely to be a cost-effective
alternative in patients with dementia, especially in
women not older than 75 years (Fig. 2; panels c and d).
Uncertainty analysis
Figure 3 represents the uncertainty around threshold
values of HR (solid lines) and HRQOL (dashed lines) in
65-year-old patients with dementia while the full set of
scenarios is available at Additional file 1: Appendices
11–18. These uncertainties were plotted against a com-
mon x-axis representing the population EVPI.
Leasing
Confidence intervals around the HR threshold values
The exoskeleton would be cost-effective even if it in-
duced falls as long as it would provide a large increment
in HRQOL. Assuming that the population EVPI is £10
million, the lower 95% CI of HR would range from 1.06
(Fig. 3; panel a, solid lines) to 1.00 (Fig. 3; panel d, solid
lines) in women, while from 1.07 (Fig. 3; panel j, solid
lines) to 1.01 (Fig. 3; panel m, solid lines) in men. How-
ever, this scenario is associated with a large increment in
HRQOL, which needed to be statistically significant in
women (Fig. 3; panel a, solid lines; 95% CI: 1.24 to 1.55).
Confidence intervals around the HRQOL utility-ratio
threshold values
The use of the exoskeleton in women would be cost-
effective only if the increments in HRQOL are signifi-
cant. Assuming that the population EVPI is £10 million,
the 95% CI of the utility-ratio in women ranges from
1.15 to 1.43 (Fig. 3; panel a, dashed lines). However, the
exoskeleton would be cost-effective if the increment in
the HR of falling is no longer significant (95% CI: 0.96 to
1.89; Fig. 3 panel a, dashed lines). Conversely, the
required increment in HRQOL in men did not reach the
statistical significance (95% CI: 0.89 to 1.70. Figure 3;
panel j, dashed lines). Similarly to women, this scenario
assumed that the exoskeleton will not induce falls (HR
95% CI: 0.87 to 2.00).
Additional file 1: Appendices 11 and 12 show that the
estimates for CVD patients did not drastically differ
from those for dementia population. However, using the
exoskeleton under a leasing agreement in patients older
than 65 years will allow for larger 95% CI for HRQOL
utility-ratio (Additional file 1: Appendices 11–14).
Purchase
Confidence intervals around the HR threshold values
The exoskeleton could be cost-effective even if it in-
creased the HR of falling – albeit the cost should be no
more than £15,000. Although increasing the cost of the
device in a single payment for the NHS and PSS will im-
pact the 95% CI of the HR, the consequences are more
evident for the HRQOL. Assuming that the population
EVPI is £10 million and the cost of the exoskeleton is
£15,000 (Fig. 3; panel f, solid lines), the 95% CI of the
HR ranges from 1.00 to 1.94, which is paired with a
utility-ratio 95% CI ranging from 1.36 to 1.68. While, if
the exoskeleton priced at £17,500 (Fig. 3; panel g, solid
lines), the 95% CI of the HR ranges from 0.95 to 1.85
followed by a utility-ratio 95% CI contained between
1.55 and 1.91. Given the larger 95% CIs, the trends ob-
served in women were less evident in men (Fig. 3; panels
n-p, solid lines).
Confidence intervals around the HRQOL utility-ratio
threshold values
Smaller increments in HRQOL would be still accept-
able if balanced by a decrement in the uncertainty
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around HR. The cost of the exoskeleton in the pur-
chase scenarios has a prominent influence on the HR
95% CI. For example, assuming that the population
EVPI is £2.5 million, the 95% CI of the HR of falling
ranges from 0.68 to 0.95 and it is paired with a
utility-ratio ranging from 1.76 to 1.96 (Fig. 3; panel h,
dashed lines). Given the larger 95% CIs, the trends
observed in women were less evident in men (Fig. 3;
panels n-p, dashed lines).
Additional file 1: Appendices 15 and 17 showed no
difference between the estimates for CVD and dementia
patients (Additional file 1: Appendices 16 and 18). Using
Fig. 3 Uncertainty analysis: 95% confidence interval of HRQOL utility-ratio, 95% confidence interval of SHF hazard ratio as a function of the
expected value of information at population level (£ million). Abbreviations: Health Related Quality of Life (HRQOL); Expected Value of Perfect
Information (EVPI). Legend: dashed lines (HRQOL utility-ratio threshold); solid lines (hazard ratio threshold)
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the exoskeleton under a purchase agreement in patients
older than 65 years will allow for larger 95% CIs for
HRQOL utility-ratio as well as narrower 95% CIs for the
HR of falling.
Discussion
Our study analysed the population EVPI to perform an
early economic assessment of an exoskeleton preventing
SHFs in high-risk populations in the UK. Based on
expert opinions and assuming a maximum acceptable
ICER is £20,000, further research would be justifiable in
patients not older than 75 years old, especially in
women. The limited number of potential male users led
to smaller population EVPI, which resulted in larger
acceptable uncertainty for males. This seems to suggest
that the intervention may more easily satisfy cost-
effectiveness requirements for male patients.
Our secondary analyses showed that the exoskeleton
could still represent good value for money even if it does
not meet the experts’ expectations. Given that the exoskel-
eton can be cost-effective even in extreme scenarios, such
as those simulating an HR of falling not inferior to 1, a
placebo effect on HRQOL may be sufficient to obtain an
ICER below £20,000/QALY. Conversely, the reduction in
the HR of falling should be significant if the manufacturer
aspires to sell the device at more than £17,500 or seeks an
indication for dementia patients older than 65 years. As
noted in the base-case, sex influenced our uncertainty
analyses. The confidence intervals of the parameters for
male patients are typically larger than confidence intervals
of the parameters for women. While, the increment of
HRQOL for male should not be necessarily statistically
significant, especially at larger population EVPI, women
will need to have narrower confidence intervals.
The two most recent systematic reviews identified nu-
merous techniques used during the early stages of product
development [14, 22]. The use of simulation and elicitation
methods are becoming the most common tools to support
the investments in the early stages [22]. These reviews cor-
roborate the importance of scenario analysis in early Health
Technology Assessment (HTA) – albeit deploying this ap-
proach in early evaluations could be more computationally
intensive than in standard evaluations. Given this computa-
tional burden, early HTA models usually obtain the un-
known parameters, and their uncertainty, using elicitation
methods. Model assumptions are then tested running a
limited number of scenarios, which provide an incomplete
scenario analysis. Although expert elicitation plays a prom-
inent role in decision-making, it is not exempt from limita-
tions, such as overconfidence and the availability of a
sufficient number of experts [23]. Given the early stage of
the exoskeleton development, we feared an exacerbation of
these limitations. Thus, we desisted from using expert
elicitation in favour of richer scenario analysis.
Although our analyses required a computationally
expensive and sophisticated approach, we also believe
that one of the strengths of our study is the objective
results of our scenario analysis, which deliberately ex-
plored even unlikely scenarios. Running 16,848 scenarios
allowed a mapping of the combinations of the exoskel-
eton requirements leading to an ICER below £20,000 per
QALY. Two-hundred and eighty-six cost-effective
scenarios were identified and, by doing so, we answered
questions (i) and (ii) outlined in the background. The
uncertainty around the parameters was then modelled
for these 286 cost-effective scenarios, obtaining further
22,880 scenarios providing the population EVPI. There-
fore, we back-calculated the maximum uncertainty
allowed around the exoskeleton parameters conditional
on population EVPI and, hence, answered the question
(iii). The answers to questions (i-iii) are necessarily com-
plex and should be interpreted by the decision maker
alongside the future evidence on the exoskeleton
performance [24]. Although answering question (iv) is
beyond the objectives of this study, our results encour-
age the manufacturer to explore alternative business
models and strategies of the production process. Reducing
the cost, or the leasing fee, of the exoskeleton, will relax
most of the requirements – especially on the HRQOL do-
main. Given that the HRQOL is likely to be a driver of the
exoskeleton cost-effectiveness, engineers should take extra
care of the design. For example, the exoskeleton should
not interfere with patients’ day-to-day activities and
should mitigate the anxiety due to a possible second fall
[25]. In this respect, the decision makers will need to
evaluate carefully the evidence on the impact of the
exoskeleton on patients’ HRQOL. Besides the thorough
scenario analysis, another strength lies in the data used for
this study. In populating the model, we used administra-
tive records from the UK population, which provided a
valuable foundation for this simulation.
However, the study is not exempt from limitations.
We did not account for higher costs occurring in more
severe comorbid patients, such as individuals with CVD
or dementia. Although the Charlson Comorbidity Index
is an important cost predictor for the primary hip
fracture, its impact is limited on the SHFs and, thus, it
was not included in the final equations [7]. Secondly,
our model did not account for spontaneous fractures
and, therefore, it might underestimate the total number
of SHFs. However, we anticipate this assumption is
unlikely to have a material impact on our estimates since
we simulated populations highly prone to fall [26]. Thirdly,
we acknowledge that a meta-analysis of the HRQOL util-
ities, accounting for either CCI or the included comorbidi-
ties, would have been the ideal approach. Given the early
stage of the exoskeleton, we deemed the disease-specific
disutilities reported by Sullivan et al. to be fit for our
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economic evaluation [18]. Finally, we used the population
EVPI, which monetised the overall uncertainty around the
cost-effectiveness of the exoskeleton. Although calculating
the expected value of perfect information for parameters
(EVPPI) would have allowed us to estimate the impact of
the uncertainty of the single parameters, EVPI was pre-
ferred because of research goals and feasibility issues. Given
the early stage of the exoskeleton, we believe that the exo-
skeleton could be tested in a research setting aiming at
goals including but not limited to the device assessment.
Therefore, using EVPI provided a broader view on the
monetary value of additional research compared to EVPPI.
Additionally, performing an EVPPI would have been largely
more computationally intensive than implementing the
analysis of the population EVPI, which was already challen-
ging because of the large number of scenarios.
Conclusion
The current paper illustrated the use of population EVPI
to identify the patients that could benefit most from the
use of a new technology, the cost-effectiveness requisites
of the technology and the necessary conditions for justify-
ing future research. To inform the decision makers, we
focused on these necessary conditions, while we neglected
numerous scenarios where the device would still represent
good value for money. Future research should fill these
gaps and, thus, provide a complete picture of the EVPI
function to support decisions on whether the development
of technologies is worthwhile.
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